



2023 IMPACT REPORT

Accelerating Cure



Table of Contents

04

aMoon at a Glance

08


Accelerating Cure
Our Impact Thesis

17

Responsible Investing
Our ESG Framework

20

**Investor Additionality &
the Global HealthTech
Ecosystem**



Our Commitment to Impact & Accelerating Cure

MANAGING PARTNERS FOREWORD



Yair Schindel, MD, MBA



Tomer Berkovitz, PhD

As we present our fourth annual Impact Report, we remain at the frontlines of life-changing advancements in health, continuing to witness and support transformational breakthroughs that shape the future of healthcare.

Our commitment to impact is integrated into our investment process. From initial screening through to active portfolio management, we evaluate each company's potential to enhance longevity and quality of life, drive scientific progress, and improve healthcare delivery, while also generating substantial value for all stakeholders.

Innovation continues to drive a paradigm shift within the healthcare sector, revolutionizing the \$10 trillion industry at an

unprecedented pace. As Israel's largest HealthTech fund, we are proud to be at the forefront of this revolution, collaborating with medical professionals, scientists, and tech entrepreneurs who are redefining how we prevent, diagnose, and treat diseases.

This year, we are excited to share our first submission to the UN Principles for Responsible Investment (PRI), marking a significant milestone in our journey to incorporate Environmental, Social, and Governance (ESG) principles into our investment practices. Becoming a UN PRI signatory has furthered our commitment to responsible investing, and we have made substantial progress in developing our framework for evaluating ESG risks and opportunities. Our goal is to integrate ESG

considerations thoughtfully into our investment processes, from diligence to portfolio management.

Our mission to create long-lasting impact remains at the heart of our work. This report is a testament to our commitment to advancing technologies that enable people to live longer, healthier, and better lives. We are proud to share the ways in which our dedication to impact is reflected in our work and look forward to continuing to drive meaningful change in the healthcare industry.

Chapter 01

aMoon at a Glance

Our HealthTech Investment Platform

2017


Founded

Dedicated Platform

Alpha, IR & Communications, Finance & Operations, Legal, Compliance

35

Portfolio
Companies



2

aMoon Locations

Ra'anana, Israel | Boston, MA



40+

Team
Members

8

Co-Investments


3

Investment Vehicles

Velocity



Growth



Edge



\$1.3B

AUM

120+

Global
Limited Partners



aMoon Culture & Mindset

We are a team of scientists, physicians, entrepreneurs, and investors with global experience who are working tirelessly to advance solutions that will help people live healthier, better lives.

We firmly believe collaboration among team members with varied experiences generates more incisive and deeper insights that better serve our investors, portfolio companies and community.

Our commitment to these values is unwavering – and is central to our core mission to accelerate cure. We recognize the value of varied perspectives in furtherance of our mission and in solving the complex problems of a changing-and increasingly diverse-world.

We aim to fulfill the following objectives to unleash the potential of a dedicated and committed mix of people:



Enhance employee engagement and collaboration




Recruit, develop and retain talented employees from all backgrounds and experiences



Expand our impact and community engagement across HealthTech hubs around the globe


WORK EXPERIENCE



EDUCATION



LANGUAGE & CULTURE



Our 2023 Investments

\$61.7 million

This past year, we invested in exciting new companies and continued to support our existing portfolio companies with additional investments as they progressed toward major milestones in their journey to accelerating cure.



Our Investment Impact

\$3.0 billion

Raised by our portfolio companies in the public and private rounds during and after our initial investment



Chapter 02

Accelerating Cure

Our Impact Thesis

Our Impact Thesis

At aMoon, we believe that creating long-lasting impact and sustainable value is deeply connected to our ability to advance technologies that help people live healthier, longer, and better lives.

Our impact assessment manifests across the entire investment cycle; from screening, through investing, to monitoring our portfolio.

We have defined five impact pillars that derive from our mission to accelerate cure:



Save & extend lives

Save or meaningfully extend life: innovations that can cure diseases and save lives through breakthrough treatments.



Improve quality of life

Improve the quality of life for those with chronic diseases: treatments for some of the most challenging unmet needs.



Increase access to care

Better access to healthcare: we back cutting-edge technologies aiming to democratize healthcare and ensure access to affordable, quality health services for all.



Enable breakthrough discoveries

Enabling the development of groundbreaking technologies transforming the way we diagnose and treat disease.














Reduce costs

As healthcare costs rise to unsustainable levels we focus on increasing institutions' capacity and cutting costs.

Innovation Index

























VELOCITY

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE BREAKTHROUGH DISCOVERIES	IMPACT STAGE*
	█	█				1
	█				█	1
	█			█	█	1
		█	█	█		3
			█	█		3
	█		█	█		3
		█	█	█		3
			█	█	█	3
	█	█		█	█	1
	█				█	1
	█				█	2

*Impact stage 1 Early Development 2 Late Development 3 Early Commercialization 4 Late Commercialization

Innovation Index

GROWTH I & II

COMPANY	SAVE & EXTEND LIVES	IMPROVE QUALITY OF LIFE	INCREASE ACCESS TO CARE	REDUCE COSTS	ENABLE BREAKTHROUGH DISCOVERIES	IMPACT STAGE*
 AKOYA BIOSCIENCES <small>THE SPATIAL BIOLOGY COMPANY</small>	█				█	4
 Adicet Bio	█	█			█	2
 ALTRUBIO	█			█	█	2
 aya:a	█					2
 Better Life PARTNERS	█	█	█	█	█	3
 BiojicDesign	█				█	1
 biosplice	█	█				2
 CartiHeal		█		█		3
 conniehealth			█	█		3
 KAR	█	█				2
 MDCLONE	█			█	█	3
 MiNA Therapeutics	█				█	1
 MOBILion SYSTEMS, INC. <small>Revealing What Others Cannot See</small>					█	3
 omada		█	█	█		4
 prognomiQ	█		█		█	1
 Satellite ^{BI}	█	█			█	1
 scipher MEDICINE	█	█	█	█	█	3
 seer					█	3
 SERA PROGNOSTICS <small>The Prognosis Company</small>	█			█	█	3
 SOPHiA GENETICS	█	█			█	4
 theranica		█		█		3
 ULTIMA GENOMICS				█	█	3
 viracta	█					2
 zebra MEDICAL VISION	█		█	█		2

*Impact stage 1 Early Development 2 Late Development 3 Early Commercialization 4 Late Commercialization



SAVE & EXTEND LIVES

HARNESSING AI TO DESIGN ANTIBODIES AGAINST COMPLEX TARGETS IN AUTOIMMUNE DISEASES AND ONCOLOGY

Therapeutic antibodies typically have much higher specificity compared with conventional drugs, driving a better ratio between efficacy and side effects. Designing antibodies against therapeutic targets that are difficult to access and complicated to manipulate is of high importance in the drug discovery field.

Biologic Design uses proprietary computer-guided techniques to design novel antibodies against complex therapeutic targets. Using 3D modeling the company is able to characterize antibody binding sites with a very high degree of precision and then make amino acid level changes to dramatically improve their functionality and precision. Biologic's technology develops new potential for the power and capabilities of antibody technology to unlock the full potential of well-studied biological pathways.

\$100B+

GLOBAL ANTIBODY MARKET SIZE

~45%

OF THE COMMERCIAL AND PIPELINE DRUGS ARE ANTIBODY BASED BIOLOGIC DRUGS

\$260B

IN ANTIBODY THERAPEUTIC MARKET IS EXPECTED BY 2025



IMPROVE QUALITY OF LIFE

OFF-THE-SHELF IMPLANTS FOR THE TREATMENT OF CARTILAGE AND BONE DEFECTS

Cartilage injuries affect millions of patients around the world, causing severe pain and disability. Once damaged, hyaline cartilage has a very limited ability to heal spontaneously. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine's most challenging unmet needs.

CartiHeal has developed an off-the-shelf implant, utilizing unique types of corals, that regenerates natural cartilage for treatment of cartilage and bone lesions in knee joints. CartiHeal's flagship Agili-C implant represents a significant medical breakthrough and unique approach to stimulating cartilage regeneration and bone remodeling.

600K

KNEE REPLACEMENT PROCEDURES PER YEAR IN THE US

\$3.5B

GLOBAL KNEE CARTILAGE REPAIR MARKET SIZE

~30M

PEOPLE AFFECTED BY OSTEOARTHRITIS IN THE US



EMPOWERING RECOVERY: SUBSTANCE USE DISORDER TREATMENT WHENEVER, WHEREVER

Better Life Partners (BLP) is a tech-enabled behavioral healthcare services company that has developed a novel care delivery platform for treating patients with substance use disorders (SUDs).

BLP's distinctive approach combines a boots-on-the-ground presence, active collaboration with various local community stakeholders, and a comprehensive offering of both in-person and virtual outpatient treatment options, catering to the diverse patient needs.

With a specific focus on building trust and increasing self-efficacy, BLP has been able to improve longitudinal outcomes and lower rates of drug use, emergency room visits, and hospitalizations among members.

REDUCE COSTS

5,300+
PATIENTS TREATED

72%
SIX-MONTH
RETENTION RATE



POWERING THE FUTURE OF BEHAVIORAL HEALTH

The behavioral healthcare industry is extremely overburdened. Clinicians report high levels of burnout, with greater demand from patients than care they can supply. With pen and paper as the primary, and often only, tools for keeping patient notes to make diagnoses and recommendations, a more efficient tool is needed to provide new actionable insights that enable clinicians to make data-informed decisions and reduce their administrative burden.

Eleos Health has developed advanced AI-backed workflow solutions for behavioral health to power the delivery of evidence-based behavioral care. Its platform runs in the background of therapy sessions to surface key clinical insights while generating clinical documentation that reduces the administrative burden on the clinicians, case managers, and field-based providers. In addition, the platform scales compliance review and data reporting tasks.

INCREASE ACCESS TO HEALTHCARE

40%

Reduction in administrative burden on mental health clinicians by using Eleos

15,000

Projected shortage of behavioral health practitioners in the US by 2025

METASIGHT

DEMOCRATIZING NEXT-GENERATION METABOLOMICS

There is a significant need to develop non-invasive diagnostic methods for early identification of disease. In their early stages, diseases can be detected by tracking shifts in the profile of blood metabolites through the science of metabolomics. There is a major barrier to wide adoption of metabolomic profiling due to test timelines and costs, limiting its current use to just a few diseases and high-risk populations.

MetaSight's technology produces high throughput, unbiased metabolomic profiling of blood samples at \$1 per sample and in less than one minute of processing linked to longitudinal electronic medical records, developing predictive biomarker tests for almost all diseases at early stages. In 2023, MetaSight's serum biobank became the world's third largest (samples from 600,000 people), and its metabolomics database became the world largest (450,000 samples).

ENABLE BREAKTHROUGH DISCOVERIES

\$4B

MARKET FOR DIAGNOSED NASH
PATIENTS ELIGIBLE FOR DRUG
TREATMENT IN THE US

\$20B

COLON CANCER
SCREENING MARKET
IN THE US

700K+

ANALYZED SAMPLES

Chapter 03

Responsible Investing

Our ESG Framework

ESG INVESTOR LENS

Integrating ESG into our Practices & Investment Lifecycle

At aMoon, we integrate Environmental, Social, and Governance considerations (ESG) into our daily operations as well as into our investment process.

Internally, we are incorporating ESG into our ownership policies and practices.

In our investment engine & process, we are integrating ESG into our investment analysis by examining the policies and practices of potential portfolio companies to ensure better governance, diversity, and resilience. We also monitor and track our portfolio's ESG progress in order to identify gaps and value creation opportunities.

ENVIRONMENT

- Environmental impact
- Climate change & business model resilience

SOCIAL

- Diversity & Inclusion
- Human Capital development & corporate culture

GOVERNANCE

- Corporate governance
- Board governance
- Cyber & Data privacy

aMoon's ESG Roadmap

INTERNAL

Integrating ESG at the organizational level

● COMPLETED

● ONGOING

● NEXT STEP



EXTERNAL

Integrating ESG into our investment lifecycle

● COMPLETED

● ONGOING

● NEXT STEP



Chapter 04

Investor Additionality & the Global HealthTech Ecosystem

Spikes Program

Our internal "Spikes" Program helps us get ahead of the curve through continuous learning in some of the most exciting and disruptive fields in HealthTech.

SELECT AREAS OF INTEREST

Liquid Biopsy

Behavioral Health

AI-Based Discovery

Obesity

Women's Health

Gene & RNA Therapies

Value-Based Care

Collaborations & Partnerships

Joining forces with leading pharmaceutical companies, strategics, academic institutions, and ecosystem players to accelerate HealthTech innovation

The Explorer Program



Powered by aMoon and Merck (M Ventures), Explorer targets high-impact proposals for sponsored translational academic research in key areas we believe are on the verge of major transformation.



StarFinder Digital Innovation Lab is an exclusive early-stage collaboration program powered by aMoon and Roche.

Now in its 4th year, StarFinder assists early-stage ventures developing highly disruptive AI-based technologies in diagnostics to reach Proof of Concept.

Initially focused on Israel, the program has since expanded to Boston, Singapore, Australia and South Korea – building bridges between vibrant HealthTech hubs around the world and creating opportunities for collaboration.

LEAP



A partnership between aMoon, 8200Bio, and BMC Innovation, in collaboration with AWS, LEAP is a first-of-its-kind program that brings together exceptional tech talent and practicing clinicians to form the next wave of HealthTech Startups.

Bina



A scientific unit at the Weizmann Institute of Science, Bina's purpose is to identify early-stage research projects with the potential to develop into an applied research program.

aMoon is a close collaborator of Bina, often partnering with the program and hosting workshops with the Bina Innovation Fellows.



8400 pioneers a powerful network of 2,000+ Israeli ecosystem leaders and innovators across sectors to build a HealthTech powerhouse. aMoon takes an active role in 8400's strategic ecosystem collaborations to realize opportunities and close ecosystem gaps.



A community-based acceleration program for women in VC, bringing together skilled investors with seasoned VC leaders to diversify investment committees and the allocation of funds they are responsible for.

Leveraging Our Network to Unlock Opportunities Through *aMoon Alpha*

CAPITAL

We supported

23 Companies

With

52%

conversion rate

including:

Follow-on investments due to our introductions

PAYERS & PROVIDERS

We supported

12 Companies

With

68%

conversion rate

including:

Establishing collaborations with Payers & Providers

STRATEGICS

We supported

28 Companies

With

48%

conversion rate

including:

Development collaborations and licensing agreements

TALENT

We supported

18 Companies

With

56%

conversion rate

including:

C-level and Board Member Placements

STORYTELLING

We supported

17 Companies

With

82%

conversion rate

including:

Strategic communications support and media placements

Building bridges between HealthTech hubs around the globe

Global HealthTech Hubs

Prominent centers for HealthTech innovation

Limited Partners

Our investors include large global banks, well known institutional investors, as well as family offices, foundations, and individuals

Portfolio Companies

Completed 35 investments in HealthTech companies since inception

aMoon Locations

Our principal office is in Ra'anana, Israel , with a satellite office in Boston, MA

aMoon Team Members' Experience

Our multi-disciplinary team is composed of scientists, physicians, engineers, entrepreneurs and investors with global experience



Portfolio Companies in the News

aMoon in the News

Ultima Genomics ranked in top 11 most promising biotech companies of 2023

[READ MORE](#)

Eleos listed as one of the most promising digital health companies in 2023

[READ MORE](#)

MetaSight Diagnostics highlighted as one of 20 Israeli companies to watch in 2023

[READ MORE](#)

CartiHeal Acquired by Smith & Nephew

[READ MORE](#)

Altru Bio's records Positive topline data from its Phase 1 trial

[READ MORE](#)

Ibex Medical Analytics, Roche, and AWS partner for AI-enabled digital pathology solutions

[READ MORE](#)

aMoon's HealthTech Roundup: Q2 2023

[READ MORE](#)

Paving the Way for Targeted Medicine: What Does the Future Hold for Tools & Diagnostics?

[READ MORE](#)

Leveraging LEAP to Form the Next Wave of HealthTech Startups

[READ MORE](#)

Platform to Pipeline Transformation

[READ MORE](#)

Unlocking ASCO 2023: aMoon's Key Takeaways

[READ MORE](#)

The Marvelous World of mRNA: A Kariko Moment of Pride

[READ MORE](#)

Disclaimer

This presentation (including all information contained herein) is being delivered to parties for the purposes of learning about aMoon's impact. It is provided on a confidential basis to allow readers to learn more about aMoon (the "Fund").

This presentation is being provided to you for the sole purpose of affording you with background information about the Fund's business. Neither the presentation nor anything contained herein forms the basis of any contract or commitment. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Fund and is qualified in its entirety by the information to be made available by the Fund to persons meeting certain investment criteria and not to the public in general.

It is hereby clarified that the offering of interests in the Fund is a private offering and does not constitute and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), and the interests have not been registered nor is there an intention to register them, under the Israeli Securities Law, or under the laws of any other jurisdiction. Investors in the interests will not be able to rely on such securities law in many matters related to or deriving from their investment in the Fund. The interests will be offered and sold under exemptions provided by the Israeli Securities Law in connection with the foregoing, therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. Neither the Israeli Securities Authority nor the regulatory authority of any other country, state or jurisdiction has approved or will approve this presentation or the interests referred to herein.

Any representation to the contrary is unlawful.

Neither the General Partner nor the management company, intend to register as an investment adviser, an investment marketer or an investment portfolio manager under the Israeli Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management Law, 5755-1995, and neither of them carries insurance as set forth under the aforesaid laws. Nothing in this presentation constitutes legal, accounting or tax advice or individually tailored investment advice. It is further clarified that the interests in the Fund are not being registered under the U.S. Securities Act of 1933. The interests are being offered in a private placement and each investor will be required to make certain representations, including but not limited to (a) that it is an accredited investor as defined in Regulation D under the Securities Act, (b) that it is acquiring an interest in the Fund for its own account, for investment purposes only and not with a view to its distribution, and (c) that it has received or had access to all information it deems relevant to evaluate the merits and risks of the prospective investment. This presentation is not intended for, and does not constitute an offer to sell or the solicitation of an offer to buy, any interests in the Fund, to any person to whom such an offer or solicitation is unlawful or not authorized.

While we have endeavored to ensure that all data herein is accurate, no representation, express or implied, is made as to the accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("Forward Looking Statements"). Such Forward Looking Statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases are outside the control of the Fund and its managers and general partner).

By participating in this presentation or by retaining a copy of this presentation, you agree to be bound by the foregoing limitations. This presentation (including all information contained herein) is being delivered on a confidential basis.

The presentation is the property of the Fund and no part of the presentation may be disclosed, distributed or reproduced to any third party without the consent of the Fund. The offering of interests in the Fund is a private offering and is not intended to constitute an "offer to the public" as defined in the Israeli Securities Law 5729-1968 (the "Israeli Securities Law"), therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. This presentation does not constitute an offer to invest in the Fund.

This document is issued by aMoon Ventures Y. SH. Ltd Company number 515563377 (aMoon) as a Corporate Authorised Representative (AR No. 001292024) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (Polar Advisory). aMoon's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the aMoon Growth Fund II L.P. only to wholesale clients. This document is provided on a confidential, personal and private basis for use only by the recipient as a wholesale client under the Corporations Act 2001 (Cth) and should not be forwarded to others. The information contained in this document is of a general nature only and is not to be taken to contain any financial product advice or recommendation. Nothing in this document is intended as financial product advice and it does not take into account any person's investment objectives, financial circumstances or specific needs. This document is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the aMoon Growth Fund II L.P. aMoon and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.